Daprodu Tablets 1mg 30 Tablets

What it is used for: Anemia.

Indications as listed by the manufacturer: Daprodustat is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. Limitations of Use : Daprodustat is not indicated for use : As a substitute for red blood cell transfusions in patients who require immediate correction of anemia. For treatment of anemia of chronic kidney disease in patients who are not on dialysis .

How it works: Daprodustat is a reversible inhibitor of HIF-PH1, PH2 and PH3 (IC50 in the low nM range). This activity results in the stabilization and nuclear accumulation of HIF-1a and HIF-2a transcription factors, leading to increased transcription of the HIF-responsive genes, including erythropoietin.

Active ingredient: Daprodustat.

Reported side effects: Following adverse reaction have been reported with the use of Daprodustat : Increased risk of death, myocardial Infarction, stroke, venous thromboembolism, and thrombosis of vascular access, risk of hospitalization for heart failure, hypertension, gastrointestinal erosion, retinal hemorrhage, hypersensitivity (rash, dermatitis, urticaria), stomach ache, constipation and peripheral edema.

Known drug interactions: CYP2C8 Inhibitors Concomitant administration of strong CYP2C8 inhibitors (e.g., gemfibrozil) with Daprodustat is contraindicated due to a marked increase in Daprodustat exposure. Concomitant administration of moderate CYP2C8 inhibitors (e.g., clopidogrel) increases Daprodustat exposure. Reduce the starting dose of Daprodustat by half when initiating treatment in patients on clopidogrel or a moderate CYP2C8 inhibitor except in patients whose starting dose is already 1mg. Monitor hemoglobin and adjust the dose of Daprodustat when initiating or stopping therapy with clopidogrel or a moderate CYP2C8 inhibitor during treatment with Daprodustat. CYP2C8 Inducers CYP2C8 inducers (e.g., rifampin) may decrease Daprodustat exposure, which may result in loss of efficacy. Monitor hemoglobin and adjust the dose of Daprodustat when initiating or stopping therapy with CYP2C8 inducers during treatment with Daprodustat .

Adults : One tab daily . Children : Not recommended .

Follow your doctor’s instructions. The dosage above is the usual range — your prescription takes precedence over it.

Active ingredient: Daprodustat. Labelled strength: 1mg.

Store this medicine at room temperature, away from direct light and heat.

Manufactured by Daprodu Pharma (Pvt) Ltd.. Country of origin: Switzerland.